載入...
Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer
Over the last few decades, improved and more individualized treatment has contributed to the increased survival rate of patients with breast cancer. However, certain patients may receive excessive treatment resulting in undesired side effects. In a previous study, it was demonstrated that systemical...
Na minha lista:
| 發表在: | Mol Clin Oncol |
|---|---|
| Main Authors: | , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
D.A. Spandidos
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7087479/ https://ncbi.nlm.nih.gov/pubmed/32257197 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2020.2014 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|